论文部分内容阅读
Objectives To provide evidence that rosuvastatin could improve insulin-resistance and inhibit atherogenesis by modulating insulin signalling, and whether this effect beyond its plasma cholesterollowering effect.Methods Thirty-two 6-week-old low-density lipoprotein receptor deficient (LDLR-/-) mice were randomised into four groups (n =8 in each group): Normal control group (NC);High fat and high fructose diet group (HFF);HFF plus rosuvastatin group (HFFR);HFFR plus mevalonic acid group (HFFRMA).